A new drug called Ryanodex is currently being tested to combat the hyperthermia that is often induced due to MDMA use. Eagle Pharmaceuticals, Inc. is the company behind the new drug that recently reached an agreement with the National Institutes of Health (“NIH”) / National Institute on Drug Abuse (“NIDA”).
"We are very pleased to be working alongside the NIH to explore the potential of Ryanodex to reduce elevated body and brain temperature resulting from the use of Ecstasy and Methamphetamine," said Scott Tarriff, the President and Chief Executive Officer of Eagle Pharmaceuticals, to Street Insider.
Hyperthermia is a common side effect of ingesting MDMA and ecstasy that can be extremely dangerous and sometimes fatal. Having a drug that combat those side effects can potentially save lives, especially at music festivals where these cases occur.
“We believe that Ryanodex has the potential to provide benefit to patients experiencing pathological thermal dysregulation associated with the use of Ecstasy and Methamphetamine,” stated Adrian Hepner, Executive Vice President and Chief Medical Officer.
Preclinical trials for Ryanodex are due to take place this summer with results expected to arrive in late 2016 or early 2017.